🧬 AI Against Cancer: Tempus, AstraZeneca, and Pathos Build a Next-Gen Oncology Platform
At the intersection of biotechnology and artificial intelligence, a new chapter in the fight against cancer is beginning. Tempus AI, AstraZeneca, and Pathos AI have joined forces to develop a multimodal AI model capable of analyzing and interpreting clinical, molecular, and imaging data to support oncology decision-making.
The parties officially announced their partnership, based on a long-term agreement between Tempus and AstraZeneca that began in 2021.
Under the updated deal, AstraZeneca will pay $35 million to Tempus AI for access to its vast data sets, analytic services, and infrastructure.
What sets this project apart is its multimodal approach — combining data from various sources: genomic profiles, histology images, medical records, and lab tests. This allows not only for disease progression forecasting but also for identifying optimal therapy regimens, including adaptive immunotherapy and personalized targeted treatments.
Pathos AI will be responsible for the technical implementation: model development, training, and testing. The company specializes in interpretable AI systems, which is crucial in medicine where transparency isn’t a luxury — it’s a requirement.
The synergy between biopharma, AI infrastructure, and clinical data makes this alliance particularly significant. This isn’t about a prototype — it’s a real step toward algorithm-driven medicine, firmly grounded in scientific and clinical standards.
